Protocol summary

Study aim
Comparison of the effect of prophylactic injection of doses of 4 and 8 mg of intravenous Ondansetron on nausea and itching after spinal injection of Fentanyl in spinal anesthesia, in lower limb orthopedic surgery
Design
A controlled, parallel-group, triple-blind, randomized, phase 2 clinical trial on 90 patients. The lottery is used for randomization
Settings and conduct
This is a three-blind randomized clinical trial that will be conducted on 90 patients candidate for orthopedic surgery under spinal anesthesia in Kashani Hospital, Isfahan. After the approval of the ethics committee and obtaining the consent of the patients, the patients are randomly assigned into groups, in each group the desired intervention is applied and the clinical symptoms of the patient are recorded. The researcher who records the patient's symptoms, the analysts who collect the data analyzed during the study, and the patients did not know the type of intervention applied in each group, so they were all blind.
Participants/Inclusion and exclusion criteria
Inclusion criteria: age 18 to 65 years, ASA anesthesia class I and II, candidate for lower limb orthopedic surgery under spinal anesthesia, and consent to participate in the study. Non-Inclusion criteria: addiction to cigarettes, narcotics, and psychotropic substances, allergy to any of the drugs used, presence of skin infection at the injection site, anti-nausea use in the last 24 hours, pregnancy and breastfeeding
Intervention groups
Intervention group A: Patients in this group receive 8 mg of ondansetron (equivalent to 4 ml) intravenously 30 minutes after spinal. Intervention group B: Patients in this group receive 4 mg of ondansetron (equivalent to 4 ml) intravenously 30 minutes after spinal. Control group C: Patients in this group receive 4 mg of 4 ml of distilled water intravenously 30 minutes after spinal
Main outcome variables
nausia, itching

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20160307026950N47
Registration date: 2022-10-12, 1401/07/20
Registration timing: registered_while_recruiting

Last update: 2022-10-12, 1401/07/20
Update count: 0
Registration date
2022-10-12, 1401/07/20
Registrant information
Name
Behzad Nazemroaya
Name of organization / entity
Isfahan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 31 3212 3543
Email address
behzad_nazem@med.mui.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-09-23, 1401/07/01
Expected recruitment end date
2023-03-21, 1402/01/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the effect of prophylactic injection of doses of 4 and 8 mg of intravenous Ondansetron on nausea and itching after spinal injection of Fentanyl in spinal anesthesia, in lower limb orthopedic surgery
Public title
Investigating the effect of Ondansetron on nausea and itching caused by spinal Fentanyl injection
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Patients 18 to 65 years old Anesthesia class I and II according to ASA criteria Candidate for lower limb surgery under spinal anesthesia Informed consent to enter the study
Exclusion criteria:
History of smoking, drug and psychedelic addiction Allergy to any anesthetic drugs, Ondansetron and fentanyl History of coagulation disorders High ICP Pregnancy or breastfeeding Skin infection at the injection site Anti-nausea use in the last 24 hours
Age
From 18 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 90
Randomization (investigator's opinion)
Randomized
Randomization description
This is a simple randomized clinical trial in which patients entered the study groups by lottery; The medicines and placebo are placed in sealed, opaque, and similar form packets coded. Each code is also written on a piece of paper, folded, and placed inside a box. After entering the operating room, each patient takes one of the papers out of the box; The pocket with the same number is the intervention that will apply to him. This process continues till the number of patients will reach the desired one.
Blinding (investigator's opinion)
Triple blinded
Blinding description
This is a three-way blind clinical trial; In this way, the researcher who records the patient's symptoms is different from the person who injects the drug and has no knowledge of the type of drug and is blind. The analysts who analyze the data collected during the study also don't know the type of intervention in any group and they are blind. Even though the patients are included in the study, they do not know the type of intervention and are blind.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences
Street address
Hezar Jarib
City
Isfahan
Province
Isfehan
Postal code
8174673461
Approval date
2022-07-31, 1401/05/09
Ethics committee reference number
IR.MUI.MED.REC.1401.182

Health conditions studied

1

Description of health condition studied
Spinal anesthesia
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Severity of nausea
Timepoint
Every 5 minutes after spinal until 15 minutes and then every 15 minutes until the end of the 4th hour
Method of measurement
Nausea and vomiting severity behavioral scale questionnaire

2

Description
Itching scale
Timepoint
Every 5 minutes after spinal until 15 minutes and then every 15 minutes until the end of the 4th hour
Method of measurement
Itching severity scale questionnaire

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 8 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.
Category
Prevention

2

Description
Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.
Category
Prevention

3

Description
Control group C: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 ml of distilled water manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Kashani Hospital
Full name of responsible person
Behzad Nazemoroaya
Street address
Kashani St
City
Isfahan
Province
Isfehan
Postal code
8183983434
Phone
+98 31 3233 0091
Email
behzad_nazem@med.mui.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shaghayegh Haghjoo
Street address
Hezar Jarib
City
اصفهان
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3668 0048
Email
research@mui.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Sepide Hasani
Position
Anesthesiology resident
Latest degree
Medical doctor
Other areas of specialty/work
Anesthesiology
Street address
Hezar Jarib
City
Isfahan
Province
Isfehan
Postal code
8146713543
Phone
+98 31 3620 2020
Email
sepideh.hassani@yandex.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Behzad Nazem roaya
Position
Professor assistant of Anesthesia and Intensive carentensive care
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Hezar Jarib
City
Isfahan
Province
Isfehan
Postal code
8146713543
Phone
+98 31 3620 2020
Email
behzad_nazem@med.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Leyla Rafiei
Position
Nurse Anesthetist
Latest degree
Bachelor
Other areas of specialty/work
Anesthesiology
Street address
Hezar Jarib
City
Isfahan
Province
Isfehan
Postal code
8146713543
Phone
+98 31 3620 2020
Email
Leylarafiei943@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...